Approach and Progress

What Precision Therapeutics Means to Us

Human genetics is at the core of our therapeutic and development strategies. To build our pipeline, we focused on patients first — particularly patients with a high genetic risk profile. We assessed the functional implications of their underlying mutations. We then matched each molecular abnormality with an appropriate therapeutic candidate. We are currently pursuing three distinct genetically defined patient populations in our ocular portfolio.

A Truly Multimodal Process

We’re focused on finding the best therapeutic solutions for patients — and we’re not limited to a single approach. We have carefully selected a panel of technologies well-suited to each target that human genetics has defined for us. This strategy has resulted in a broad and diverse pipeline, including monoclonal antibodies, recombinant proteins and gene therapies.

Gemini Pipeline

Our broad pipeline spans three genetically-defined targets in our ocular portfolio and three modalities including recombinant proteins, monoclonal antibodies, and gene therapies.

Ocular Portfolio
Phase 1
Phase 2
GR 1009
Target 1
GR 1005
GR 1006
Target 2
GR 1017
GR 1008
Target 3
Systemic Portfolio
GR 1007
Target 1

Our Partners

We are proud to partner with leading research institutions and innovative companies around the world, including:

  • The University of Edinburgh
  • Newcastle University
  • Sanquin
  • StrideBio